Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Novavax's 2024-2025 Formula COVID-19 vaccine, NVX-CoV2705, receives EUA from FDA for use in individuals aged 12+ to prevent COVID-19. The vaccine targets JN.1, a 'parent strain' of currently circulating variants, and is available in pre-filled syringes at thousands of locations nationwide. The CDC recommends its use, and it includes Matrix-M adjuvant for enhanced immune response.
Reference News
Novavax's 2024-2025 Formula COVID-19 vaccine, NVX-CoV2705, receives EUA from FDA for use in individuals aged 12+ to prevent COVID-19. The vaccine targets JN.1, a 'parent strain' of currently circulating variants, and is available in pre-filled syringes at thousands of locations nationwide. The CDC recommends its use, and it includes Matrix-M adjuvant for enhanced immune response.
Novavax received EUA from FDA for its updated Covid-19 vaccine, NVX-CoV2705, targeting Omicron variant JN.1 strain, usable for individuals 12 years and older. CEO John C Jacobs highlighted the vaccine's robust cross-reactivity against JN.1 lineage viruses, aligning with FDA's recent recommendations for monovalent JN.1 vaccines.